A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis

← catalyst calendar

NCT07171983 · readout in 313 d

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

46estimated

Sites

Country

India

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-02-27

actual

When the study began enrolling

Primary completion

2027-06-28

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-08-25

estimated

The whole study's end, after follow-up

First posted

2025-09-15

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-20

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Rheumatoid Arthritis

Interventions

Drug: BMS-986454
Other: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Number of participants with adverse events (AEs)

measured Up to 6 months

Number of participants with serious adverse events (SAEs)

measured Up to 6 months

Number of participants with physical examination findings

measured Up to 6 months

Number of participants with vital sign measurement findings

measured Up to 6 months

Number of participants with 12-lead electrocardiogram (ECG) findings

measured Up to 6 months

Number of participants with clinical laboratory test findings

measured Up to 6 months

Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed